Imunon, Inc. quarterly report, Q1 FY2020

Business context and reporting period

This is Celsion Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 15, 2020. Although the request identifies Imunon, the filing names Celsion Corporation as the registrant (ticker CLSN). Celsion was a clinical-stage oncology drug developer, with ThermoDox in a Phase III liver-cancer trial and GEN-1 in development for ovarian cancer.

Financial results and liquidity

MetricQ1 2020Q1 2019 or comparison
Technology development and licensing revenue$125,000$125,000
Research and development expense$3.05 million$2.77 million
General and administrative expense$1.84 million$2.22 million
Total operating expenses$4.89 million$4.99 million
Loss from operations$4.77 million$4.86 million
Net loss$5.06 million$2.37 million
Basic and diluted loss per share$0.20$0.12
Net cash used in operating activities$4.98 million$5.54 million
Cash and cash equivalents at period-end$5.75 million$3.58 million

Revenue was licensing-related, not product revenue. Operating expenses exceeded revenue substantially; a profit margin is not meaningful for this development-stage company. Net loss increased largely because Q1 2019 included a $3.13 million non-cash gain from revaluing the earn-out liability, whereas Q1 2020 recorded a $41,000 non-cash charge. Operating loss improved by about $95,000 year over year.

At March 31, current assets were $18.88 million and current liabilities $7.43 million, giving working capital of $11.45 million, versus $8.34 million at December 31, 2019. Cash, short-term investments, accrued investment interest and the New Jersey NOL-sale receivable totaled about $17.5 million. The company reported $9.90 million of note payable, net of financing costs, and $1.44 million of operating lease liabilities. Operating cash use was partly offset by $5.79 million of net equity proceeds; cash declined by $1.13 million during the quarter.

Material changes and financing

  • R&D expense rose 10.3% to $3.05 million, including increased GEN-1/OVATION 2 development spending; OPTIMA Study costs declined year over year.
  • G&A expense fell 17.0% to $1.84 million, primarily from lower personnel, stock-compensation and professional-fee costs.
  • The February 2020 registered offering raised approximately $4.8 million gross from 4.57 million shares and included warrants; the company exchanged the original warrants for warrants covering 3.2 million shares at a higher $1.24 exercise price. It also sold shares under its Aspire facility before terminating that agreement in March.
  • In April, the company received approximately $1.8 million from selling New Jersey net operating losses. It received a $632,220 Paycheck Protection Program loan but returned the proceeds in full on May 13, 2020. On that date, Horizon agreed to defer the first two principal payments, totaling $833,333, due in August and September 2020.
  • Management said available resources, future NOL sales and remaining capacity under the JonesTrading equity facility were expected to fund operations through mid-2021. This is a forecast, not a guarantee; management also said additional capital may be needed sooner or in greater amounts than anticipated.

Outlook, risks and unusual items

  • The OPTIMA Phase III trial had reached its 158-death threshold for the second planned interim analysis, announced April 15. At filing, the independent monitoring committee was expected to meet in July 2020; the filing does not report that analysis’s outcome. The earlier 128-event review recommended continuing the trial, but company discussion of blinded data and historical subgroup results should not be treated as proof of efficacy.
  • For GEN-1, the company reported preliminary OVATION 2 surgical-resection results and an orphan-drug recommendation from the EMA committee. These are early-stage findings and do not establish clinical benefit or regulatory approval.
  • COVID-19 had not materially affected Q1 results according to the company, but could disrupt clinical enrollment and operations, supply chains, regulatory timelines and access to financing. The magnitude was not determinable.
  • The company expected operating losses to continue and had approximately $296 million of cumulative losses. Development, trial, regulatory and commercialization outcomes remain uncertain; further equity financing could dilute shareholders.
  • A shareholder derivative and putative class action alleged fiduciary-duty breaches related to approval of the 2018 Stock Incentive Plan. The matter was at an early stage and its outcome was not determinable.
  • The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

  1. Confirm the filing entity: this 10-Q is for Celsion Corporation, not a registrant named Imunon.
  2. Check the outcome and timing of the OPTIMA second interim analysis, and distinguish independent committee conclusions from company-reported historical or blinded comparisons.
  3. Assess cash burn, the mid-2021 runway assumption, available equity-facility capacity and potential dilution, including outstanding warrants and options.
  4. Review the Horizon loan terms and deferred payments, the completed NOL sale proceeds, and the return of the PPP loan when evaluating liquidity.
  5. Monitor COVID-19 effects on trial conduct and supply, the shareholder litigation, and any impairment or valuation updates for acquired intangible assets and goodwill.